Complete Genomics announced that it has agreed to be acquired by Swiss Rockets AG, a Switzerland-based life sciences group, in a transaction subject to customary closing conditions and approval by MGI shareholders.
The deal is designed to enable the scaling of Complete Genomics’ innovation pipeline and diversification of its manufacturing capacity. Upon closing, Swiss Rockets will own 100 percent of Complete Genomics and will have sole control of the company.
Despite the change in ownership, Complete Genomics will continue operating as a U.S.-based company. Its existing management team will retain responsibility for day-to-day operations, product strategy, software development, and customer relationships. Following the close of the transaction, Dr. Vladimir Cmiljanovic will serve as CEO, with the broader management team to be announced at a later date.
Swiss Rockets is focused on targeted cancer therapies and next-generation vaccines. Complete Genomics, which has a long history in next-generation sequencing and novel chemistries and technologies, is expected to complement Swiss Rockets’ strategy by expanding access to precision medicine and enabling the development of new therapies and diagnostics.
The companies emphasized that customers should expect full continuity across products, services, software, data handling practices, and support. Existing customer agreements will remain unchanged, and all software on Complete Genomics sequencers will continue to be managed and maintained by its U.S.-based software development team.
Founded in 2005, Complete Genomics provides end-to-end DNA sequencing platforms, reagents, and software for research applications. The company says it has supported more than 10,900 scientific publications worldwide.
KEY QUOTES:
“Swiss Rockets recognized Complete Genomics’ strong position in developing and delivering cost-effective, flexible sequencing solutions and saw an opportunity to accelerate innovation and expand market reach. We are excited to support the team as they expand their technology portfolio, strengthen supply chain resilience, and accelerate their impact on genomics research worldwide.”
Dr. Vladimir Cmiljanovic, Founder, CEO and Chairperson, Swiss Rockets AG
“This transaction positions Complete Genomics for its next phase of growth. Swiss Rockets shares our long-term vision for sequencing innovation and supports our strategy to expand product adoption, strengthen operational independence, and progressively diversify our manufacturing and supply chain footprint.”
Dr. Rade Drmanac, Founder, Complete Genomics
